RTTNews | Aug 3, 2021 10:19AM EDT

10:18 Tuesday, August 3, 2021 (RTTNews.com) - Arcturus Therapeutics Holdings Inc. (ARCT) shares are trading more than 28 percent higher on Tuesday morning after the company reported approval of Singapore clinical trial application to advance ARCT-154 and ARCT-165.

The clinical-stage messenger RNA medicines company said it received approval for clinical trial application from the Singapore Health Sciences Authority to enable the advancement of two STRR mRNA vaccine candidates into the clinic. The next-gen vaccines will target SARS-CoV-2 variants in Phase 1/2 study.

Currently, shares are at $45.15, up 30.27 percent from the previous $34.66 on a volume of 1,531,401. For the 52-week period, the shares have traded in a range of 24.87 - 129.71 on average volume of 504,917.

Read the original article on RTTNews ( https://www.rttnews.com/3215312/arcturus-therapeutics-gains-30-on-singapore-approval-for-sars-cov-2-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved